PHILADELPHIA, April 16, 2015 — Premier Research will present a speaker and host two roundtable sessions at the World Orphan Drug Congress, April 22-24 in Washington, DC. The Philadelphia-based contract research organization is a platinum sponsor of the fifth annual event, a top meeting place for biopharma, biotechs, government, patient groups, and others.
An April 23 presentation by Emily Stube, Director, Medical Writing Services, Global Regulatory Affairs, will explore attaining expedited review approvals and agreements for Phase 3 orphan drug development programs.
Also on the 23rd, Angi Robinson, Executive Director and Scientific Account Leader, will host a roundtable discussion about how to run successful rare disease studies.
On April 24, Nach Dave, Director of Regulatory Affairs, leads a roundtable talk on advancing use of regulatory science to aid clinical trial design and performance for pediatric rare diseases.
Premier Research also will showcase its hands-on expertise — spanning more than 100 rare disease studies — at the event, taking place at the Washington Hilton in Washington, DC.
About Premier Research
Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in such areas as analgesia, CNS, rare diseases, medical device and diagnostics, and pediatric research. Premier Research operates in 50 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively.